Replies to post #229021 on Biotech Values

[Biotech Investr]

Thanks

[miljenko]

<Covid-19 testing is low-margin business.>
Yes, in general, but from what they charge now...$200 in US (20e in EU), it is far from low-margin. That may change, still big chunk of that $8.3B was for testing. Some micro-b may make millions? I have no idea which one!

[DewDiligence]

PKI announces 1Q20 guidance shortfall for sales and earnings:

https://www.businesswire.com/news/home/20200309005274/en

PKI is a big player in diagnostics, although I don't think they are doing COVID-19 testing.

[DewDiligence]

US testing capacity for COVID-19 boosted by Roche test and (belated) government actions:

https://www.biocentury.com/article/304649

Roche’s stock is +5% in US trading (RHHBY) and +4% in Switzerland (ROG.SW), moves that equate to a (unduly) large increase in market cap.